Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
27
datasets available to search
ShareScore release 0.9.0
Dataset results
27 results for “mucormycosis”
Deciphering the Neurosensory Olfactory Pathway and Associated Neo-Immunometabolic Vulnerabilities Implicated in COVID-Associated Mucormycosis (CAM) and COVID-19 in a Diabetes Backdrop—A Novel Perspective
<p>Raw data files of transcriptomic profiling experiments, which form the basis for our publication (https://www.mdpi.com/2673-4540/3/1/13).</p>
Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India
<p><strong>Abstract</strong></p> <p><strong><em>BACKGROUND</em></strong></p> <p>In the context of the ongoing COVID-19 pandemic increased incidence of ROCM was noted in India, among those infected with COVID. We determined risk factors for rhino-orbito-cerebral mucormycosis (ROCM) post Coronavirus disease 2019 (COVID-19) among those never and ever hospitalized for COVID-19 separately through a multi-centric, hospital-based, unmatched case-control study across India.</p> <p><strong><em>METHODS</em></strong></p> <p>We defined cases and controls as those with and without post-COVID ROCM, respectively. We compared their socio-demographics, comorbidities, steroid use, glycaemic status, and practices. We calculated crude and adjusted odds ratio (AOR) with 95% confidence intervals (CI) through logistic regression. The covariates with p-value for crude OR of less 0·20 were considered for the regression model.</p> <p><strong><em>RESULTS</em></strong></p> <p>Among hospitalised, we recruited 267 cases and 256 controls and 116 cases and 231 controls among never hospitalised. Risk factors (AOR; 95% CI) for post-COVID ROCM among the hospitalised were age 45-59 years (2·1; 1·4 to 3·1), having diabetes mellitus (4·9; 3·4 to 7·1), elevated plasma glucose (6·4; 2·4 to 17·2), steroid use (3·2; 2 to 5·2) and frequent nasal washing (4·8; 1·4 to 17). Among those never hospitalised, age ≥ 60 years (6·6; 3·3 to 13·3), having diabetes mellitus (6·7; 3·8 to 11·6), elevated plasma glucose (13·7; 2·2 to 84), steroid use (9·8; 5·8 to 16·6), and cloth facemask use (2·6; 1·5 to 4·5) were associated with increased risk of post-COVID ROCM.</p> <p><strong><em>CONCLUSIONS</em></strong></p> <p>Hyperglycemia irrespective of having diabetes mellitus and steroid use was associated with increased risk of ROCM independent of COVID-19 hospitalisation. Rational steroid usage and glucose monitoring may reduce the risk of post-COVID.</p>
Mucormycosis or Black fungus dataset
<p>Archival bundle of mucormycosis fear assessment and it's association with insomnia alog with other variables among Banlgadeshi health workers.</p>
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
ClinicalTrials.gov study NCT00419770. IPD Sharing: Not stated. Countries: 1. Publications: 5.
A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
ClinicalTrials.gov study NCT03816176. IPD Sharing: NO. Countries: 3. Publications: 1.
Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis
ClinicalTrials.gov study NCT06495905. IPD Sharing: NO. Countries: 1. Publications: 1.
Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
ClinicalTrials.gov study NCT05097664. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
ClinicalTrials.gov study NCT06878144. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis
ClinicalTrials.gov study NCT02845934. IPD Sharing: NO. Countries: 1. Publications: 0.
Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
ClinicalTrials.gov study NCT06900114. IPD Sharing: Not stated. Countries: 1. Publications: 0.
World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt
ClinicalTrials.gov study NCT06267326. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
ClinicalTrials.gov study NCT07185503. IPD Sharing: NO. Countries: 1. Publications: 0.
Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value
ClinicalTrials.gov study NCT07339800. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Post-COVID-19 Mucormycosis in Critical Care
ClinicalTrials.gov study NCT05911035. IPD Sharing: NO. Countries: 1. Publications: 0.
Mucormycosis in ICU
ClinicalTrials.gov study NCT03387696. IPD Sharing: NO. Countries: 1. Publications: 0.
Descriptive Epidemiology on Management of Mucormycosis
ClinicalTrials.gov study NCT03429023. IPD Sharing: Not stated. Countries: 1. Publications: 0.
COVID-19 and Rhino-orbital Mucormycosis
ClinicalTrials.gov study NCT05212961. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
ClinicalTrials.gov study NCT07191756. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Endoscopic Surgical Treatment of Rhino-Sinusal Mucormycosis
ClinicalTrials.gov study NCT02226705. IPD Sharing: Not stated. Countries: 1. Publications: 0.
COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital
ClinicalTrials.gov study NCT05074043. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.